thought leadership
Optimizing access to cell and gene therapies in the Asia-Pacific region: 4 considerations
Vesshnu Sutharsan, Consultant | December 1, 2023
In the Asia-Pacific (APAC) region, the demand for cell and gene therapies (CGTs) is increasing but the reimbursement environment for these therapies is still nascent. This update, from our expert insights report, summarizes how a one-size-fits-all approach will not work across APAC markets; fostering strategic collaborations within local ecosystems, coupled with awareness and policy shaping efforts is needed to enable optimal CGT access.
4 considerations for optimizing access to cell and gene therapies in the Asia-Pacific region
A one-size-fits-all approach will not work across APAC markets because value determination frameworks are diverse, with mature markets and emerging markets in APAC having differing priorities. The diverse needs and challenges across the APAC region demand a nuanced and collaborative mindset from manufacturers looking to commercialize their CGTs. For global products, a tailored approach that respects local realities and fosters partnerships within local ecosystems is crucial.
For a deep dive into these considerations
Read the full report, “Cell and gene therapy market access in the Asia-Pacific region”
Supporting your Policy, Access, Value, and Evidence in the Asia-Pacific region
The expert APAC team at Avalere Health will help you bring out the best in your asset, using our extensive market access and disease area experience.
The APAC region is characterized by its dynamic nature and rapidly evolving markets. These are critical to the future growth plans of our biopharmaceutical clients and we are leading many groundbreaking market access projects in the region.
We’re based in Singapore, experienced, easy to talk to, and we love a challenge. Let us show you why our clients come back to work with us time and again. Contact us.